Hyperpolarized [2– 13 C]Pyruvate Identifies a Mitochondria‐Active Hepatocellular Carcinoma Phenotype With Vulnerability to Mitochondrial Inhibition
NMR in Biomedicine · 2026-09 · 39 (9)
DOI: 10.1002/nbm.70360 ↗Kurz gefasst
Fachartikel in der Zeitschrift NMR in Biomedicine, online erschienen am 05.08.2026. Verfasst von Qianhui Dou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Pyruvic Acid, Mitochondria. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIA NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) exhibits metabolic heterogeneity that is not fully characterized by glycolysis‐focused spectroscopic profiling. This study investigated whether in vitro hyperpolarized (HP) [2‐ 13 C]pyruvate NMR spectroscopy can identify a mitochondria‐active HCC phenotype and assess its association with sensitivity to mitochondrial metabolic inhibition. HP [2‐ 13 C]pyruvate NMR spectroscopy was used to evaluate mitochondrial metabolism in McA‐RH7777 HCC cells, with N1S1 cells serving as a glycolysis‐dominant reference. Cell viability following treatment with the glutaminase inhibitor BPTES and the mitochondrial metabolic inhibitor CPI‐613 was assessed by MTT assay, and metabolic changes following CPI‐613 treatment were further evaluated using HP [2‐ 13 C]pyruvate. HP [2‐ 13 C]pyruvate demonstrated enhanced pyruvate‐to‐glutamate conversion in McA‐RH7777 cells, whereas N1S1 showed minimal glutamate labeling. CPI‐613 treatment resulted in a dose‐dependent reduction in cell viability, while BPTES produced limited effects. Although pyruvate‐to‐glutamate conversion did not significantly decrease following CPI‐613 treatment, pyruvate‐to‐lactate conversion increased, indicating metabolic adaptation. These findings demonstrate that HP [2‐ 13 C]pyruvate enables functional identification of a mitochondria‐active HCC phenotype characterized by enhanced pyruvate‐to‐glutamate conversion. This approach may facilitate metabolic subtype classification, help identify tumors susceptible to mitochondrial metabolic inhibition, and enable non‐invasive monitoring of treatment‐induced metabolic adaptation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.
- Myocardial Biology Unit, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
- Polarize ApS, Frederiksberg, Denmark.
- Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Abdominal Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Qianhui Dou, Sophia M Mirrione, Karen Dos Santos, Samuel R Calos, Aaron K Grant, Yi-Fen Yen, Leo L Tsai
Förderung
- NIH HHS
- NIA NIH HHS
- NIBIB NIH HHS
- Massachusetts General Hospital
- National Institutes of Health
Zitieren
APA
Dou, Q., Mirrione, S. M., Santos, K. D., Calos, S. R., Grant, A. K., Yen, Y. F., & Tsai, L. L. (2026). Hyperpolarized [2– 13 C]Pyruvate Identifies a Mitochondria‐Active Hepatocellular Carcinoma Phenotype With Vulnerability to Mitochondrial Inhibition. NMR in Biomedicine, 39(9). https://doi.org/10.1002/nbm.70360
Vancouver
Dou Q, Mirrione SM, Santos KD, Calos SR, Grant AK, Yen YF, et al. Hyperpolarized [2– 13 C]Pyruvate Identifies a Mitochondria‐Active Hepatocellular Carcinoma Phenotype With Vulnerability to Mitochondrial Inhibition. NMR in Biomedicine. 2026;39(9). doi:10.1002/nbm.70360
BibTeX
@article{Dou2026,
author = {Dou, Qianhui and Mirrione, Sophia M and Santos, Karen Dos and Calos, Samuel R and Grant, Aaron K and Yen, Yi-Fen and Tsai, Leo L},
title = {Hyperpolarized [2– 13 C]Pyruvate Identifies a Mitochondria‐Active Hepatocellular Carcinoma Phenotype With Vulnerability to Mitochondrial Inhibition},
journal = {NMR in Biomedicine},
year = {2026},
volume = {39},
number = {9},
doi = {10.1002/nbm.70360}
}
EUVIMED